Literature DB >> 17962984

The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus.

J E Stalenhoef1, B Alisjahbana, E J Nelwan, J van der Ven-Jongekrijg, T H M Ottenhoff, J W M van der Meer, R H Nelwan, M G Netea, R van Crevel.   

Abstract

As patients with diabetes mellitus are at increased risk of developing tuberculosis, we hypothesized that this susceptibility to mycobacterial infection is due to a defective Th1-cytokine response. To explore this hypothesis, we examined four groups of subjects in Indonesia: 23 patients with tuberculosis, 34 patients with tuberculosis and diabetes, 32 patients with diabetes only and 36 healthy controls. Ex-vivo production of interferon (IFN)gamma, tumour necrosis factor-alpha and interleukin (IL)-1beta, 6, 10, -12 and -4 was measured following stimulation with Mycobacterium tuberculosis, Escherichia coli lipopolysaccharide and phytohaemagglutinin. Patients with active tuberculosis were found to have lower IFNgamma levels and a higher production of other pro-inflammatory cytokines and IL-4, both in the presence and absence of diabetes. Diabetes patients without tuberculosis, however, showed strongly reduced non-specific IFNgamma production, which is essential for inhibition of the initial growth of M. tuberculosis. Our data suggest that a defective non-specific immune response in diabetes may contribute to an increased susceptibility to develop tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962984     DOI: 10.1007/s10096-007-0395-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  29 in total

1.  Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans.

Authors:  Christian P Fischer; Lisbeth B Perstrup; Annika Berntsen; Peter Eskildsen; Bente K Pedersen
Journal:  Clin Immunol       Date:  2005-08-19       Impact factor: 3.969

2.  Increased interleukin-12 plasma concentrations in both, insulin-dependent and non-insulin-dependent diabetes mellitus.

Authors:  G Winkler; O Dworak; F Salamon; D Salamon; G Speer; K Cseh
Journal:  Diabetologia       Date:  1998-04       Impact factor: 10.122

3.  Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment.

Authors:  Edhyana Sahiratmadja; Bachti Alisjahbana; Tjitske de Boer; Iskandar Adnan; Anugrah Maya; Halim Danusantoso; Ronald H H Nelwan; Sangkot Marzuki; Jos W M van der Meer; Reinout van Crevel; Esther van de Vosse; Tom H M Ottenhoff
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

4.  Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy.

Authors:  C S Hirsch; Z Toossi; C Othieno; J L Johnson; S K Schwander; S Robertson; R S Wallis; K Edmonds; A Okwera; R Mugerwa; P Peters; J J Ellner
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

Review 5.  Control of human host immunity to mycobacteria.

Authors:  Tom H M Ottenhoff; Frank A W Verreck; Marieke A Hoeve; Esther van de Vosse
Journal:  Tuberculosis (Edinb)       Date:  2004-12-31       Impact factor: 3.131

6.  [The relation between diabetes mellitus and IFN-gamma, IL-12 and IL-10 productions by CD4+ alpha beta T cells and monocytes in patients with pulmonary tuberculosis].

Authors:  K Tsukaguchi; H Okamura; M Ikuno; A Kobayashi; A Fukuoka; H Takenaka; C Yamamoto; T Tokuyama; Y Okamoto; A Fu; M Yoshikawa; T Yoneda; N Narita
Journal:  Kekkaku       Date:  1997-11

7.  Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products.

Authors:  B F Liu; S Miyata; H Kojima; A Uriuhara; H Kusunoki; K Suzuki; M Kasuga
Journal:  Diabetes       Date:  1999-10       Impact factor: 9.461

8.  Incidence of pulmonary tuberculosis among diabetics.

Authors:  S J Kim; Y P Hong; W J Lew; S C Yang; E G Lee
Journal:  Tuber Lung Dis       Date:  1995-12

9.  Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo.

Authors:  Christian Lienhardt; Annalisa Azzurri; Amedeo Amedei; Katherine Fielding; Jackson Sillah; Oumou Y Sow; Boubacar Bah; Marisa Benagiano; Alimou Diallo; Roberto Manetti; Kebba Manneh; Per Gustafson; Steve Bennett; Mario M D'Elios; Keith McAdam; Gianfranco Del Prete
Journal:  Eur J Immunol       Date:  2002-06       Impact factor: 5.532

10.  NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis.

Authors:  Gerben Ferwerda; Stephen E Girardin; Bart-Jan Kullberg; Lionel Le Bourhis; Dirk J de Jong; Dennis M L Langenberg; Reinout van Crevel; Gosse J Adema; Tom H M Ottenhoff; Jos W M Van der Meer; Mihai G Netea
Journal:  PLoS Pathog       Date:  2005-11-25       Impact factor: 6.823

View more
  47 in total

1.  Type 2 diabetes mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary tuberculosis.

Authors:  Nathella P Kumar; Rathinam Sridhar; Dina Nair; Vaithilingam V Banurekha; Thomas B Nutman; Subash Babu
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

2.  Degradation of myxovirus virion RNA by periodate.

Authors:  G A Tannock; I P Griffith
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

Review 3.  Diabetes and immunity to tuberculosis.

Authors:  Nuria Martinez; Hardy Kornfeld
Journal:  Eur J Immunol       Date:  2014-02-16       Impact factor: 5.532

4.  Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.

Authors:  S E Medellín-Garibay; N Cortez-Espinosa; R C Milán-Segovia; M Magaña-Aquino; J M Vargas-Morales; R González-Amaro; D P Portales-Pérez; S Romano-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

5.  Diabetes mellitus and risk of all-cause mortality among patients with tuberculosis in the state of Georgia, 2009-2012.

Authors:  Matthew J Magee; Mary Foote; David M Maggio; Penelope P Howards; K M Venkat Narayan; Henry M Blumberg; Susan M Ray; Russell R Kempker
Journal:  Ann Epidemiol       Date:  2014-02-08       Impact factor: 3.797

6.  Adults with Mycobacterium tuberculosis infection and pre-diabetes have increased levels of QuantiFERON interferon-gamma responses.

Authors:  Matthew J Magee; Susanna L Trost; Argita D Salindri; Genet Amere; Cheryl L Day; Neel R Gandhi
Journal:  Tuberculosis (Edinb)       Date:  2020-04-02       Impact factor: 3.131

7.  The effect of diabetic control status on the clinical features of pulmonary tuberculosis.

Authors:  S W Park; J W Shin; J Y Kim; I W Park; B W Choi; J C Choi; Y S Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-25       Impact factor: 3.267

8.  Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases.

Authors:  Blanca I Restrepo; Aulasa J Camerlin; Mohammad H Rahbar; Weiwei Wang; Mary A Restrepo; Izelda Zarate; Francisco Mora-Guzmán; Jesus G Crespo-Solis; Jessica Briggs; Joseph B McCormick; Susan P Fisher-Hoch
Journal:  Bull World Health Organ       Date:  2011-03-30       Impact factor: 9.408

9.  Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes.

Authors:  Blanca I Restrepo; Susan P Fisher-Hoch; Brian Smith; Sangchoon Jeon; Mohammad H Rahbar; Joseph B McCormick
Journal:  Am J Trop Med Hyg       Date:  2008-10       Impact factor: 2.345

Review 10.  Epidemic inflammation: pondering obesity.

Authors:  Carl Nathan
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.